Results 131 to 140 of about 18,181 (226)

International biosimilar medicines review of the literature: quarterly update January 2020 - March 2020

open access: yes, 2020
This report provides an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform activities related to GBMA Education’s Biosimilar Education Grant, these reviews examine all international and ...
Ward, M., Staff, K., Reuter Lange, S.
core  

A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany

open access: yesInternational Journal of Women's Health, 2019
Weiguang Xue,1 Adam Lloyd,1 Edel Falla,1 Claudia Roeder,2 Rudiger Papsch,2 Klaus Bühler3,41IQVIA, Real-World Evidence, London, UK; 2Merck KGaA, Frankfurt, Germany; 3Centre for Gynecology Endocrinology & Reproductive Medicine Kinderwunsch-Zentrum
Xue W   +5 more
doaj  

[Successful switch from originator to biosimilar growth hormone: patients' experiences]

open access: yes, 2017
OBJECTIVE: To survey patients' experiences with the switch from an originator biologic to a biosimilar growth hormone. DESIGN: Questionnaire. METHOD: We developed a questionnaire in which patients were asked about their experiences with the switch from ...
Repping-Wuts, H.   +7 more
core  

The uptake of biosimilar products by British formularies

open access: yes, 2015
OBJECTIVES: A “biosimilar” is a biological medicine similar to a licensed biological medicine (“originator”). As of October 2014, six biosimilars are licensed and marketed in Great Britain (GB) (three biosimilar filgrastims, two biosimilar epoetins and ...
Murray Smith (17167576)   +2 more
core   +1 more source

Biosimilars in diabetic macular edema: Promise, progress, and pitfalls. [PDF]

open access: yesIndian J Ophthalmol
Jain V   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy